Barclays Maintains Overweight on Sempra, Raises Price Target to $105

Benzinga Newsdesk www.benzinga.com Positive 85.8%

Neg 0% Neu 0% Pos 85.8%

Barclays analyst Nicholas Campanella maintains Sempra (NYSE:SRE) with a Overweight and raises the price target from $95 to $105.